GT Biopharma, Inc. (GTBP)
USD 2.05
(-21.46%)
USD 2.05
(-21.46%)
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2023 | -13.57 Million USD | 36.13% |
| 2022 | -21.25 Million USD | 63.04% |
| 2021 | -57.51 Million USD | -750.31% |
| 2020 | -6.76 Million USD | 57.87% |
| 2019 | -16.05 Million USD | 93.58% |
| 2018 | -250.06 Million USD | -84.46% |
| 2017 | -135.57 Million USD | -1346.23% |
| 2016 | -9.37 Million USD | -5.01% |
| 2015 | -8.92 Million USD | -272.58% |
| 2014 | -2.39 Million USD | -202.14% |
| 2013 | -793 Thousand USD | 77.43% |
| 2012 | -3.51 Million USD | 10.54% |
| 2011 | -3.92 Million USD | -57.31% |
| 2010 | -2.49 Million USD | -116.0% |
| 2009 | -1.15 Million USD | 4.54% |
| 2008 | -1.21 Million USD | -8.51% |
| 2007 | -1.11 Million USD | 58.2% |
| 2006 | -2.67 Million USD | 16.27% |
| 2005 | -3.18 Million USD | -85.51% |
| 2004 | -1.71 Million USD | -122.38% |
| 2003 | -773 Thousand USD | 4.69% |
| 2002 | -811 Thousand USD | 76.51% |
| 2001 | -3.45 Million USD | 26.94% |
| 2000 | -4.72 Million USD | -7.17% |
| 1999 | -4.41 Million USD | 37.89% |
| 1998 | -7.1 Million USD | -42.0% |
| 1997 | -5 Million USD | 13.79% |
| 1996 | -5.8 Million USD | -5.45% |
| 1995 | -5.5 Million USD | -175.0% |
| 1994 | -2 Million USD | -17.65% |
| 1993 | -1.7 Million USD | -240.0% |
| 1992 | -500 Thousand USD | 0.0% |
| 1991 | -500 Thousand USD | -200.0% |
| 1990 | 500 Thousand USD | 0.0% |
| 1989 | 500 Thousand USD | 600.0% |
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2024 Q2 | -3.9 Million USD | -26.37% |
| 2024 Q1 | -3.09 Million USD | 2.43% |
| 2023 Q4 | -3.16 Million USD | -1.47% |
| 2023 Q2 | -3.62 Million USD | 1.2% |
| 2023 Q1 | -3.66 Million USD | 36.57% |
| 2023 FY | -13.57 Million USD | 36.13% |
| 2023 Q3 | -3.12 Million USD | 13.78% |
| 2022 FY | -21.25 Million USD | 63.04% |
| 2022 Q2 | -3.01 Million USD | 44.62% |
| 2022 Q1 | -5.44 Million USD | 70.06% |
| 2022 Q4 | -5.77 Million USD | 17.73% |
| 2022 Q3 | -7.02 Million USD | -133.01% |
| 2021 Q4 | -18.17 Million USD | -205.31% |
| 2021 Q1 | -29 Million USD | -1223.69% |
| 2021 Q2 | -4.38 Million USD | 84.89% |
| 2021 Q3 | -5.95 Million USD | -35.91% |
| 2021 FY | -57.51 Million USD | -750.31% |
| 2020 Q2 | -1.55 Million USD | -45.61% |
| 2020 FY | -6.76 Million USD | 57.87% |
| 2020 Q1 | -1.07 Million USD | -23.56% |
| 2020 Q4 | -2.19 Million USD | -12.65% |
| 2020 Q3 | -1.94 Million USD | -24.84% |
| 2019 Q2 | -2.27 Million USD | 43.81% |
| 2019 FY | -16.05 Million USD | 93.58% |
| 2019 Q4 | -866 Thousand USD | 90.22% |
| 2019 Q3 | -8.85 Million USD | -288.55% |
| 2019 Q1 | -4.05 Million USD | -31.18% |
| 2018 Q2 | -5.15 Million USD | 27.97% |
| 2018 FY | -250.06 Million USD | -84.46% |
| 2018 Q4 | -3.09 Million USD | 98.68% |
| 2018 Q1 | -7.16 Million USD | -21.54% |
| 2018 Q3 | -234.66 Million USD | -4450.32% |
| 2017 Q2 | -1.28 Million USD | 16.45% |
| 2017 Q4 | -5.89 Million USD | 95.36% |
| 2017 FY | -135.57 Million USD | -1346.23% |
| 2017 Q1 | -1.53 Million USD | -87.1% |
| 2017 Q3 | -126.85 Million USD | -9772.06% |
| 2016 Q4 | -822 Thousand USD | 67.51% |
| 2016 Q3 | -2.53 Million USD | -19.28% |
| 2016 Q1 | -3.9 Million USD | -34.15% |
| 2016 Q2 | -2.12 Million USD | 45.63% |
| 2016 FY | -9.37 Million USD | -5.01% |
| 2015 Q3 | -2.77 Million USD | -94.06% |
| 2015 FY | -8.92 Million USD | -272.58% |
| 2015 Q4 | -2.9 Million USD | -4.72% |
| 2015 Q1 | -1.81 Million USD | -10.29% |
| 2015 Q2 | -1.43 Million USD | 20.98% |
| 2014 Q3 | -549 Thousand USD | -427.88% |
| 2014 Q1 | -101 Thousand USD | 56.47% |
| 2014 Q2 | -104 Thousand USD | -2.97% |
| 2014 Q4 | -1.64 Million USD | -199.09% |
| 2014 FY | -2.39 Million USD | -202.14% |
| 2013 Q3 | -140 Thousand USD | -89.19% |
| 2013 FY | -793 Thousand USD | 77.43% |
| 2013 Q4 | -232 Thousand USD | -65.71% |
| 2013 Q2 | -74 Thousand USD | 78.67% |
| 2013 Q1 | -347 Thousand USD | 53.04% |
| 2012 Q2 | -1.03 Million USD | -160.1% |
| 2012 Q1 | -396 Thousand USD | 62.21% |
| 2012 FY | -3.51 Million USD | 10.54% |
| 2012 Q4 | -739 Thousand USD | 45.26% |
| 2012 Q3 | -1.35 Million USD | -31.07% |
| 2011 Q2 | -481 Thousand USD | 74.11% |
| 2011 Q3 | -541 Thousand USD | -12.47% |
| 2011 FY | -3.92 Million USD | -57.31% |
| 2011 Q4 | -1.04 Million USD | -93.72% |
| 2011 Q1 | -1.85 Million USD | -252.56% |
| 2010 Q4 | -527 Thousand USD | 19.42% |
| 2010 Q2 | -386 Thousand USD | 58.49% |
| 2010 Q3 | -654 Thousand USD | -69.43% |
| 2010 FY | -2.49 Million USD | -116.0% |
| 2010 Q1 | -930 Thousand USD | -30.25% |
| 2009 Q1 | -139 Thousand USD | 81.61% |
| 2009 FY | -1.15 Million USD | 4.54% |
| 2009 Q2 | -216 Thousand USD | -55.4% |
| 2009 Q4 | -714 Thousand USD | -720.69% |
| 2009 Q3 | -87 Thousand USD | 59.72% |
| 2008 Q3 | -426 Thousand USD | -242.95% |
| 2008 Q2 | 298 Thousand USD | 191.13% |
| 2008 FY | -1.21 Million USD | -8.51% |
| 2008 Q1 | -327 Thousand USD | 61.03% |
| 2008 Q4 | -756 Thousand USD | -77.46% |
| 2007 Q1 | -452 Thousand USD | 63.1% |
| 2007 Q2 | 405 Thousand USD | 189.6% |
| 2007 Q4 | -839 Thousand USD | -264.78% |
| 2007 FY | -1.11 Million USD | 58.2% |
| 2007 Q3 | -230 Thousand USD | -156.79% |
| 2006 Q2 | -492 Thousand USD | 15.17% |
| 2006 Q4 | -1.22 Million USD | -228.42% |
| 2006 Q1 | -580 Thousand USD | 74.32% |
| 2006 Q3 | -373 Thousand USD | 24.19% |
| 2006 FY | -2.67 Million USD | 16.27% |
| 2005 FY | -3.18 Million USD | -85.51% |
| 2005 Q4 | -2.25 Million USD | -564.41% |
| 2005 Q3 | -340 Thousand USD | -0.89% |
| 2005 Q2 | -337 Thousand USD | -33.2% |
| 2005 Q1 | -253 Thousand USD | 35.29% |
| 2004 Q2 | -1.02 Million USD | -131.53% |
| 2004 FY | -1.71 Million USD | -122.38% |
| 2004 Q4 | -391 Thousand USD | -371.53% |
| 2004 Q3 | 144 Thousand USD | 114.01% |
| 2004 Q1 | -444 Thousand USD | -117.65% |
| 2003 Q3 | -140 Thousand USD | 49.09% |
| 2003 FY | -773 Thousand USD | 4.69% |
| 2003 Q1 | -154 Thousand USD | -52.48% |
| 2003 Q2 | -275 Thousand USD | -78.57% |
| 2003 Q4 | -204 Thousand USD | -45.71% |
| 2002 FY | -811 Thousand USD | 76.51% |
| 2002 Q4 | -101 Thousand USD | 65.88% |
| 2002 Q3 | -296 Thousand USD | -88.54% |
| 2002 Q2 | -157 Thousand USD | 38.91% |
| 2002 Q1 | -257 Thousand USD | -53.89% |
| 2001 Q2 | -1.75 Million USD | -51.42% |
| 2001 FY | -3.45 Million USD | 26.94% |
| 2001 Q4 | -167 Thousand USD | 54.37% |
| 2001 Q1 | -1.15 Million USD | 20.34% |
| 2001 Q3 | -366 Thousand USD | 79.15% |
| 2000 Q2 | -1.14 Million USD | -17.96% |
| 2000 Q1 | -969 Thousand USD | -136.34% |
| 2000 FY | -4.72 Million USD | -7.17% |
| 2000 Q3 | -1.15 Million USD | -1.4% |
| 2000 Q4 | -1.45 Million USD | -25.54% |
| 1999 FY | -4.41 Million USD | 37.89% |
| 1999 Q2 | -1.8 Million USD | -50.0% |
| 1999 Q1 | -1.2 Million USD | 42.86% |
| 1999 Q3 | -1 Million USD | 44.44% |
| 1999 Q4 | -410 Thousand USD | 59.0% |
| 1998 Q1 | -1.9 Million USD | -90.0% |
| 1998 Q2 | -1.2 Million USD | 36.84% |
| 1998 Q3 | -2.2 Million USD | -83.33% |
| 1998 Q4 | -2.1 Million USD | 4.55% |
| 1998 FY | -7.1 Million USD | -42.0% |
| 1997 Q1 | -1.3 Million USD | 13.33% |
| 1997 Q3 | -1.4 Million USD | 0.0% |
| 1997 FY | -5 Million USD | 13.79% |
| 1997 Q4 | -1 Million USD | 28.57% |
| 1997 Q2 | -1.4 Million USD | -7.69% |
| 1996 Q4 | -1.5 Million USD | 0.0% |
| 1996 Q1 | -1.4 Million USD | 22.22% |
| 1996 FY | -5.8 Million USD | -5.45% |
| 1996 Q3 | -1.5 Million USD | 6.25% |
| 1996 Q2 | -1.6 Million USD | -14.29% |
| 1995 FY | -5.5 Million USD | -175.0% |
| 1995 Q4 | -1.8 Million USD | -28.57% |
| 1995 Q3 | -1.4 Million USD | 0.0% |
| 1995 Q2 | -1.4 Million USD | -75.0% |
| 1995 Q1 | -800 Thousand USD | 0.0% |
| 1994 Q3 | -800 Thousand USD | -166.67% |
| 1994 Q4 | -800 Thousand USD | 0.0% |
| 1994 FY | -2 Million USD | -17.65% |
| 1994 Q1 | -100 Thousand USD | 66.67% |
| 1994 Q2 | -300 Thousand USD | -200.0% |
| 1993 Q2 | -1 Million USD | -900.0% |
| 1993 Q3 | -400 Thousand USD | 60.0% |
| 1993 Q4 | -300 Thousand USD | 25.0% |
| 1993 FY | -1.7 Million USD | -240.0% |
| 1993 Q1 | -100 Thousand USD | 0.0% |
| 1992 Q4 | -100 Thousand USD | 0.0% |
| 1992 Q1 | -200 Thousand USD | -100.0% |
| 1992 Q2 | -100 Thousand USD | 50.0% |
| 1992 Q3 | -100 Thousand USD | 0.0% |
| 1992 FY | -500 Thousand USD | 0.0% |
| 1991 Q2 | 600 Thousand USD | -14.29% |
| 1991 Q4 | -100 Thousand USD | 0.0% |
| 1991 Q3 | -100 Thousand USD | -116.67% |
| 1991 Q1 | 700 Thousand USD | 125.0% |
| 1991 FY | -500 Thousand USD | -200.0% |
| 1990 Q1 | 1.1 Million USD | 134.38% |
| 1990 Q3 | 1 Million USD | -16.67% |
| 1990 Q4 | -2.8 Million USD | -380.0% |
| 1990 FY | 500 Thousand USD | 0.0% |
| 1990 Q2 | 1.2 Million USD | 9.09% |
| 1989 Q2 | 1.7 Million USD | 54.55% |
| 1989 FY | 500 Thousand USD | 600.0% |
| 1989 Q3 | 900 Thousand USD | -47.06% |
| 1989 Q4 | -3.2 Million USD | -455.56% |
| 1989 Q1 | 1.1 Million USD | 145.83% |
| Name | Operating Income | Operating Income Difference |
|---|---|---|
| Acurx Pharmaceuticals, Inc. | -14.57 Million USD | 6.872% |
| Adaptive Biotechnologies Corporation | -227.03 Million USD | 94.02% |
| IO Biotech, Inc. | -91.44 Million USD | 85.154% |
| VYNE Therapeutics Inc. | -29.25 Million USD | 53.599% |
| Organovo Holdings, Inc. | -15.08 Million USD | 10.009% |
| TNF Pharmaceuticals, Inc. | -17.12 Million USD | 20.715% |
| Lexaria Bioscience Corp. | -6.53 Million USD | -107.774% |
| Tonix Pharmaceuticals Holding Corp. | -118.38 Million USD | 88.532% |
| Aadi Bioscience, Inc. | -71.93 Million USD | 81.127% |
| Savara Inc. | -60 Million USD | 77.376% |
| Aerovate Therapeutics, Inc. | -81.4 Million USD | 83.324% |
| Rocket Pharmaceuticals, Inc. | -259.65 Million USD | 94.772% |
| Corbus Pharmaceuticals Holdings, Inc. | -45.07 Million USD | 69.883% |
| ZyVersa Therapeutics, Inc. | -14.42 Million USD | 5.858% |
| Soligenix, Inc. | -7.69 Million USD | -76.359% |
| Aptose Biosciences Inc. | -52.35 Million USD | 74.07% |
| NKGen Biotech, Inc. Common Stock | -29.74 Million USD | 54.36% |
| Century Therapeutics, Inc. | -146.54 Million USD | 90.736% |
| Eterna Therapeutics Inc. | -21.13 Million USD | 35.765% |
| Precision BioSciences, Inc. | -43.73 Million USD | 68.959% |
| Axsome Therapeutics, Inc. | -231.82 Million USD | 94.144% |
| Kura Oncology, Inc. | -165.8 Million USD | 91.812% |
| Xenetic Biosciences, Inc. | -4.51 Million USD | -200.639% |
| Dyadic International, Inc. | -8.22 Million USD | -64.963% |
| TScan Therapeutics, Inc. | -93.45 Million USD | 85.474% |
| IDEAYA Biosciences, Inc. | -134.42 Million USD | 89.901% |
| CytomX Therapeutics, Inc. | -6.48 Million USD | -109.377% |
| Autolus Therapeutics plc | -195.02 Million USD | 93.039% |
| Eton Pharmaceuticals, Inc. | -1.19 Million USD | -1038.926% |
| EyePoint Pharmaceuticals, Inc. | -73.66 Million USD | 81.57% |
| GRI Bio, Inc. | -11.38 Million USD | -19.224% |
| Tenaya Therapeutics, Inc. | -131.19 Million USD | 89.652% |
| IGM Biosciences, Inc. | -263.46 Million USD | 94.847% |
| Heron Therapeutics, Inc. | -110.61 Million USD | 87.727% |
| SAB Biotherapeutics, Inc. | -38.07 Million USD | 64.344% |
| Entero Therapeutics, Inc. | -15.77 Million USD | 13.917% |
| Opthea Limited | -191.84 Million USD | 92.923% |
| X4 Pharmaceuticals, Inc. | -107.52 Million USD | 87.374% |
| Atara Biotherapeutics, Inc. | -276 Million USD | 95.081% |
| Pliant Therapeutics, Inc. | -184.14 Million USD | 92.628% |
| Ligand Pharmaceuticals Incorporated | 11.94 Million USD | 213.683% |
| Surrozen, Inc. | -45.78 Million USD | 70.345% |
| Lixte Biotechnology Holdings, Inc. | -5.09 Million USD | -166.707% |
| Cingulate Inc. | -22.75 Million USD | 40.349% |
| Ovid Therapeutics Inc. | -59.28 Million USD | 77.099% |
| Sorrento Therapeutics, Inc. | -504.31 Million USD | 97.308% |
| Acelyrin, Inc. | -422.06 Million USD | 96.783% |
| Centessa Pharmaceuticals plc | -171.28 Million USD | 92.074% |
| Hepion Pharmaceuticals, Inc. | -48.44 Million USD | 71.978% |
| Arcturus Therapeutics Holdings Inc. | -78.2 Million USD | 82.64% |
| Syros Pharmaceuticals, Inc. | -128.98 Million USD | 89.475% |
| ADMA Biologics, Inc. | 21.63 Million USD | 162.759% |
| PureTech Health plc | -146.19 Million USD | 90.714% |
| Oncternal Therapeutics, Inc. | -41.71 Million USD | 67.455% |
| FibroBiologics, Inc. Common Stock | -8.88 Million USD | -52.728% |
| Barinthus Biotherapeutics plc | -83.91 Million USD | 83.822% |
| Kymera Therapeutics, Inc. | -165.53 Million USD | 91.798% |
| Synaptogenix, Inc. | -8.31 Million USD | -63.294% |
| Tiziana Life Sciences Ltd | -14.58 Million USD | 6.924% |
| ChromaDex Corporation | -5.59 Million USD | -142.472% |
| Inhibikase Therapeutics, Inc. | -20.08 Million USD | 32.423% |
| Monopar Therapeutics Inc. | -8.83 Million USD | -53.727% |
| Exelixis, Inc. | 170.88 Million USD | 107.945% |
| Akebia Therapeutics, Inc. | -46.25 Million USD | 70.65% |
| Better Therapeutics, Inc. | -38.26 Million USD | 64.518% |
| Nurix Therapeutics, Inc. | -155.06 Million USD | 91.245% |
| Apellis Pharmaceuticals, Inc. | -517.12 Million USD | 97.375% |
| Sangamo Therapeutics, Inc. | -274 Million USD | 95.045% |
| Seer, Inc. | -103.46 Million USD | 86.878% |
| Aridis Pharmaceuticals, Inc. | -29.99 Million USD | 54.736% |
| LAVA Therapeutics N.V. | -43.25 Million USD | 68.613% |
| Gritstone bio, Inc. | -154.63 Million USD | 91.221% |
| Jasper Therapeutics, Inc. | -68.86 Million USD | 80.285% |
| Avid Bioservices, Inc. | -18.67 Million USD | 27.316% |
| Insmed Incorporated | -709.62 Million USD | 98.087% |
| Panbela Therapeutics, Inc. | -51.29 Million USD | 73.533% |
| Avalo Therapeutics, Inc. | -23.44 Million USD | 42.092% |
| Fate Therapeutics, Inc. | -190.51 Million USD | 92.874% |
| MediWound Ltd. | -15.29 Million USD | 11.21% |
| BioXcel Therapeutics, Inc. | -171.78 Million USD | 92.097% |
| Fortress Biotech, Inc. | -142.34 Million USD | 90.462% |
| OmniAb, Inc. | -69.41 Million USD | 80.443% |
| Seres Therapeutics, Inc. | -107.98 Million USD | 87.428% |
| Zai Lab Limited | -366.57 Million USD | 96.297% |
| Revance Therapeutics, Inc. | -316.77 Million USD | 95.714% |
| Tarsus Pharmaceuticals, Inc. | -143.15 Million USD | 90.517% |
| Veracyte, Inc. | -85.79 Million USD | 84.176% |
| Abeona Therapeutics Inc. | -47.13 Million USD | 71.198% |
| FibroGen, Inc. | -281.81 Million USD | 95.183% |
| Apogee Therapeutics, Inc. | -93 Million USD | 85.403% |
| ContextLogic Inc. | -328 Million USD | 95.861% |
| Intensity Therapeutics, Inc. | -8.31 Million USD | -63.193% |
| Adial Pharmaceuticals, Inc. | -6.88 Million USD | -97.098% |
| HOOKIPA Pharma Inc. | -97.69 Million USD | 86.104% |
| Jazz Pharmaceuticals plc | 578.58 Million USD | 102.346% |
| Entrada Therapeutics, Inc. | -3.16 Million USD | -329.349% |
| Cyclacel Pharmaceuticals, Inc. | -25.45 Million USD | 46.662% |
| ImmuCell Corporation | -5.74 Million USD | -136.183% |
| Fortrea Holdings Inc. | 63.1 Million USD | 121.515% |
| KalVista Pharmaceuticals, Inc. | -140.44 Million USD | 90.334% |
| Jasper Therapeutics, Inc. | -68.86 Million USD | 80.285% |
| Foghorn Therapeutics Inc. | -107.9 Million USD | 87.419% |
| Ultragenyx Pharmaceutical Inc. | -569.2 Million USD | 97.615% |
| Theravance Biopharma, Inc. | -53.29 Million USD | 74.525% |
| Metagenomi, Inc. Common Stock | -78.49 Million USD | 82.704% |
| Vaxxinity, Inc. | -58.28 Million USD | 76.708% |
| BioCryst Pharmaceuticals, Inc. | -103.7 Million USD | 86.91% |
| Gain Therapeutics, Inc. | -22.25 Million USD | 38.993% |
| Creative Medical Technology Holdings, Inc. | -5.62 Million USD | -141.56% |
| Marker Therapeutics, Inc. | -14.58 Million USD | 6.895% |
| CASI Pharmaceuticals, Inc. | -25.28 Million USD | 46.297% |
| Senti Biosciences, Inc. | -92.72 Million USD | 85.359% |
| BioRestorative Therapies, Inc. | -15.22 Million USD | 10.806% |
| Apollomics, Inc. | -54.83 Million USD | 75.242% |
| 89bio, Inc. | -151.2 Million USD | 91.021% |
| Arrowhead Pharmaceuticals, Inc. | -205 Million USD | 93.378% |
| TransCode Therapeutics, Inc. | -19.41 Million USD | 30.087% |
| RAPT Therapeutics, Inc. | -127.06 Million USD | 89.315% |
| Ardelyx, Inc. | -63.27 Million USD | 78.545% |
| Pluri Inc. | -22.15 Million USD | 38.731% |
| Prothena Corporation plc | -191.03 Million USD | 92.893% |
| Pulmatrix, Inc. | -14.74 Million USD | 7.897% |
| Celularity Inc. | -192.28 Million USD | 92.94% |
| MeiraGTx Holdings plc | -137.06 Million USD | 90.095% |
| Omeros Corporation | -164.53 Million USD | 91.749% |
| Ainos, Inc. | -13.2 Million USD | -2.799% |
| Humacyte, Inc. | -100.04 Million USD | 86.43% |
| Mesoblast Limited | -58.79 Million USD | 76.909% |
| Cocrystal Pharma, Inc. | -18.55 Million USD | 26.85% |
| Cidara Therapeutics, Inc. | -24.48 Million USD | 44.549% |
| Blueprint Medicines Corporation | -486.27 Million USD | 97.208% |
| Cabaletta Bio, Inc. | -74.66 Million USD | 81.816% |
| Summit Therapeutics Inc. | -89.73 Million USD | 84.871% |
| Alaunos Therapeutics, Inc. | -34.26 Million USD | 60.382% |
| Scholar Rock Holding Corporation | -171.29 Million USD | 92.074% |
| Intellia Therapeutics, Inc. | -515.29 Million USD | 97.365% |
| Adlai Nortye Ltd. American Depositary Shares | -67.55 Million USD | 79.903% |
| Cytokinetics, Incorporated | -496.2 Million USD | 97.264% |
| Eloxx Pharmaceuticals, Inc. | -34.41 Million USD | 60.557% |
| Nutriband Inc. | -4.87 Million USD | -178.658% |
| Protara Therapeutics, Inc. | -43.61 Million USD | 68.872% |
| Roivant Sciences Ltd. | 4.24 Billion USD | 100.32% |
| Evogene Ltd. | -26.39 Million USD | 48.558% |
| Applied Therapeutics, Inc. | -64.53 Million USD | 78.963% |
| Hoth Therapeutics, Inc. | -7.69 Million USD | -76.49% |
| BridgeBio Pharma, Inc. | -607.37 Million USD | 97.765% |
| BioLineRx Ltd. | -49.69 Million USD | 72.681% |
| Atai Life Sciences N.V. | -125.47 Million USD | 89.18% |
| VistaGen Therapeutics, Inc. | -33.02 Million USD | 58.887% |
| Aurinia Pharmaceuticals Inc. | -91.69 Million USD | 85.194% |
| MediciNova, Inc. | -9.9 Million USD | -37.128% |
| Praxis Precision Medicines, Inc. | -126.37 Million USD | 89.257% |
| MiMedx Group, Inc. | 37.11 Million USD | 136.577% |
| PTC Therapeutics, Inc. | -349.4 Million USD | 96.115% |
| Cullinan Oncology, Inc. | -191.08 Million USD | 92.895% |
| Syndax Pharmaceuticals, Inc. | -229.95 Million USD | 94.096% |
| Pasithea Therapeutics Corp. | -15.97 Million USD | 15.04% |
| NRx Pharmaceuticals, Inc. | -27.58 Million USD | 50.788% |
| 4D Molecular Therapeutics, Inc. | -112.86 Million USD | 87.972% |
| Dyne Therapeutics, Inc. | -242.16 Million USD | 94.394% |
| Kiniksa Pharmaceuticals, Ltd. | -25.19 Million USD | 46.118% |
| Ventyx Biosciences, Inc. | -207.99 Million USD | 93.473% |
| Allakos Inc. | -196.05 Million USD | 93.075% |
| Fulcrum Therapeutics, Inc. | -110.66 Million USD | 87.732% |
| Corcept Therapeutics Incorporated | 107.28 Million USD | 112.654% |
| BioAtla, Inc. | -129.68 Million USD | 89.532% |
| Allogene Therapeutics, Inc. | -327.73 Million USD | 95.858% |
| Larimar Therapeutics, Inc. | -41.75 Million USD | 67.489% |
| Precigen, Inc. | -88.92 Million USD | 84.733% |
| BriaCell Therapeutics Corp. | -4.79 Million USD | -183.337% |
| XOMA Corporation | -41.84 Million USD | 67.559% |
| Kezar Life Sciences, Inc. | -105.23 Million USD | 87.1% |
| Incyte Corporation | 620.52 Million USD | 102.188% |
| Cara Therapeutics, Inc. | -121.49 Million USD | 88.826% |
| Aligos Therapeutics, Inc. | -87.42 Million USD | 84.472% |
| Reviva Pharmaceuticals Holdings, Inc. | -24.3 Million USD | 44.147% |
| CRISPR Therapeutics AG | -222.53 Million USD | 93.899% |
| Akero Therapeutics, Inc. | -172.87 Million USD | 92.147% |
| Eliem Therapeutics, Inc. | -21.46 Million USD | 36.756% |
| EyeGate Pharmaceuticals, Inc. | -8.21 Million USD | -65.304% |
| UroGen Pharma Ltd. | -65.53 Million USD | 79.285% |
| Sutro Biopharma, Inc. | -89.27 Million USD | 84.794% |
| ZIVO Bioscience, Inc. | -7.26 Million USD | -86.92% |
| Lisata Therapeutics, Inc. | -25.7 Million USD | 47.192% |
| Stoke Therapeutics, Inc. | -114.77 Million USD | 88.171% |
| Chimerix, Inc. | -93.06 Million USD | 85.412% |
| Outlook Therapeutics, Inc. | -53.12 Million USD | 74.446% |
| 60 Degrees Pharmaceuticals, Inc. | -5.15 Million USD | -163.377% |
| Enanta Pharmaceuticals, Inc. | -137.2 Million USD | 90.105% |
| Aprea Therapeutics, Inc. | -15.47 Million USD | 12.254% |
| Portage Biotech Inc. | -18.25 Million USD | 25.623% |
| OncoCyte Corporation | -25.13 Million USD | 45.99% |
| Qualigen Therapeutics, Inc. | -11.3 Million USD | -20.09% |
| Cadrenal Therapeutics, Inc. Common Stock | -7.63 Million USD | -77.863% |
| Processa Pharmaceuticals, Inc. | -11.45 Million USD | -18.495% |
| Purple Biotech Ltd. | 22.27 Million USD | 160.958% |
| NextCure, Inc. | -67.63 Million USD | 79.928% |
| ProMIS Neurosciences, Inc. | -18.89 Million USD | 28.161% |
| Dermata Therapeutics, Inc. | -8.04 Million USD | -68.816% |
| Generation Bio Co. | -138.56 Million USD | 90.202% |
| Neumora Therapeutics, Inc. Common Stock | -188.19 Million USD | 92.786% |
| Xeris Biopharma Holdings, Inc. | -44.01 Million USD | 69.152% |
| TRACON Pharmaceuticals, Inc. | -6.89 Million USD | -96.811% |
| NLS Pharmaceutics AG | -11.8 Million USD | -14.982% |
| Mineralys Therapeutics, Inc. | -84.65 Million USD | 83.964% |
| Novavax, Inc. | -566.51 Million USD | 97.604% |
| Virios Therapeutics, Inc. | -5.44 Million USD | -149.242% |
| Curis, Inc. | -48.33 Million USD | 71.911% |
| Daré Bioscience, Inc. | -30.83 Million USD | 55.979% |
| Titan Pharmaceuticals, Inc. | -7.27 Million USD | -86.56% |
| Virpax Pharmaceuticals, Inc. | -15.68 Million USD | 13.472% |
| Bicycle Therapeutics plc | -189.94 Million USD | 92.853% |
| BeiGene, Ltd. | -1.2 Billion USD | 98.876% |
| Kiromic BioPharma, Inc. | -19.93 Million USD | 31.913% |
| Alector, Inc. | -151.74 Million USD | 91.053% |
| Protagonist Therapeutics, Inc. | -93.65 Million USD | 85.504% |
| Erasca, Inc. | -141.52 Million USD | 90.407% |
| Checkpoint Therapeutics, Inc. | -52.14 Million USD | 73.966% |
| Aura Biosciences, Inc. | -84.99 Million USD | 84.027% |
| Viracta Therapeutics, Inc. | -50.69 Million USD | 73.219% |
| Chemomab Therapeutics Ltd. | -25.45 Million USD | 46.675% |
| Protagenic Therapeutics, Inc. | -4.52 Million USD | -199.891% |
| Pieris Pharmaceuticals, Inc. | -29.75 Million USD | 54.376% |
| BioMarin Pharmaceutical Inc. | 194.44 Million USD | 106.982% |
| Histogen Inc. | -10.64 Million USD | -27.558% |
| Fortress Biotech, Inc. | -142.34 Million USD | 90.462% |
| Avidity Biosciences, Inc. | -235.59 Million USD | 94.238% |
| Lyell Immunopharma, Inc. | -245.49 Million USD | 94.47% |
| Galecto, Inc. | -39.9 Million USD | 65.979% |
| InMed Pharmaceuticals Inc. | - USD | Infinity% |
| Phathom Pharmaceuticals, Inc. | -167.31 Million USD | 91.886% |
| Molecular Templates, Inc. | -10.46 Million USD | -29.715% |
| PDS Biotechnology Corporation | -43.04 Million USD | 68.461% |
| Amylyx Pharmaceuticals, Inc. | 38.8 Million USD | 134.988% |
| Amarin Corporation plc | -67.58 Million USD | 79.914% |
| TG Therapeutics, Inc. | 20.63 Million USD | 165.798% |
| Aptevo Therapeutics Inc. | -28.87 Million USD | 52.988% |
| Celldex Therapeutics, Inc. | -154.54 Million USD | 91.215% |
| Cogent Biosciences, Inc. | -208.13 Million USD | 93.477% |
| Onconetix, Inc. | -36.03 Million USD | 62.325% |
| MacroGenics, Inc. | -168.24 Million USD | 91.931% |
| Y-mAbs Therapeutics, Inc. | -25.67 Million USD | 47.117% |
| Ocuphire Pharma, Inc. | -10.56 Million USD | -28.524% |
| Adagene Inc. | -23.71 Million USD | 42.765% |
| Inhibrx Biosciences, Inc. | -219.22 Million USD | 93.807% |
| Cartesian Therapeutics, Inc. | -86.41 Million USD | 84.29% |
| Voyager Therapeutics, Inc. | 122.01 Million USD | 111.127% |
| SciSparc Ltd. | -5.77 Million USD | -135.164% |
| Revelation Biosciences, Inc. | -8.65 Million USD | -56.827% |
| Minerva Neurosciences, Inc. | -23.11 Million USD | 41.279% |
| Astria Therapeutics, Inc. | -83.03 Million USD | 83.649% |
| Black Diamond Therapeutics, Inc. | -86.46 Million USD | 84.298% |
| Arcutis Biotherapeutics, Inc. | -241.1 Million USD | 94.369% |
| Relay Therapeutics, Inc. | -373 Million USD | 96.36% |
| Alnylam Pharmaceuticals, Inc. | -282.17 Million USD | 95.189% |
| Psyence Biomedical Ltd. | -2.75 Million USD | -393.345% |
| Artelo Biosciences, Inc. | -10.28 Million USD | -31.972% |
| 2seventy bio, Inc. | -216.7 Million USD | 93.735% |
| Clene Inc. | -40.54 Million USD | 66.512% |
| Boundless Bio, Inc. Common Stock | -54.79 Million USD | 75.224% |
| GeoVax Labs, Inc. | -26.74 Million USD | 49.235% |
| Sonnet BioTherapeutics Holdings, Inc. | -18.79 Million USD | 27.759% |
| Arbutus Biopharma Corporation | -78.1 Million USD | 82.618% |
| Scopus BioPharma Inc. | -11.71 Million USD | -15.887% |
| Absci Corporation | -115.51 Million USD | 88.247% |
| XBiotech Inc. | -37.51 Million USD | 63.807% |
| ALX Oncology Holdings Inc. | -170.27 Million USD | 92.027% |
| Lyra Therapeutics, Inc. | -67.12 Million USD | 79.774% |
| Entera Bio Ltd. | -8.89 Million USD | -52.694% |
| Trevena, Inc. | -35.28 Million USD | 61.528% |
| Adaptimmune Therapeutics plc | -138.03 Million USD | 90.165% |
| Caribou Biosciences, Inc. | -116.05 Million USD | 88.303% |
| INmune Bio, Inc. | -29.74 Million USD | 54.353% |
| Citius Pharmaceuticals, Inc. | -36.73 Million USD | 63.04% |
| Tyra Biosciences, Inc. | -79.94 Million USD | 83.018% |
| Galmed Pharmaceuticals Ltd. | 7.49 Million USD | 281.207% |
| Unity Biotechnology, Inc. | -44.66 Million USD | 69.606% |
| Tenax Therapeutics, Inc. | -8.23 Million USD | -64.879% |
| Jaguar Health, Inc. | -34.29 Million USD | 60.409% |
| Clearside Biomedical, Inc. | -24.84 Million USD | 45.355% |
| NexImmune, Inc. | -29.19 Million USD | 53.495% |
| Connect Biopharma Holdings Limited | -62.07 Million USD | 78.129% |
| Clearmind Medicine Inc. | -8.74 Million USD | -55.308% |
| Coeptis Therapeutics Holdings, Inc. | -21.49 Million USD | 36.83% |
| Kronos Bio, Inc. | -121.83 Million USD | 88.857% |
| Innoviva, Inc. | 176.7 Million USD | 107.683% |
| Coherus BioSciences, Inc. | -203.19 Million USD | 93.319% |
| Regeneron Pharmaceuticals, Inc. | 4.04 Billion USD | 100.335% |
| Bolt Biotherapeutics, Inc. | -76.19 Million USD | 82.183% |
| Verastem, Inc. | -92.08 Million USD | 85.257% |
| ProKidney Corp. | -151.52 Million USD | 91.04% |
| CERo Therapeutics Holdings, Inc. | -2.93 Million USD | -362.873% |
| Imunon, Inc. | -21.03 Million USD | 35.446% |
| Viking Therapeutics, Inc. | -100.82 Million USD | 86.535% |
| Statera Biopharma, Inc. | -98.34 Million USD | 86.195% |
| ImmunityBio, Inc. | -362.25 Million USD | 96.252% |
| Korro Bio, Inc. | -84.53 Million USD | 83.94% |
| Travere Therapeutics, Inc. | -376.74 Million USD | 96.396% |
| Kineta, Inc. | -15.72 Million USD | 13.655% |
| Catalyst Pharmaceuticals, Inc. | 86.81 Million USD | 115.638% |
| Capricor Therapeutics, Inc. | -24.07 Million USD | 43.616% |
| Keros Therapeutics, Inc. | -169.94 Million USD | 92.011% |
| Celularity Inc. | -192.28 Million USD | 92.94% |
| Crinetics Pharmaceuticals, Inc. | -222.6 Million USD | 93.901% |
| CalciMedica, Inc. | -21.87 Million USD | 37.938% |
| Cibus, Inc. | -318.88 Million USD | 95.743% |
| C4 Therapeutics, Inc. | -139.03 Million USD | 90.235% |
| Marinus Pharmaceuticals, Inc. | -131.48 Million USD | 89.675% |
| Eledon Pharmaceuticals, Inc. | -43 Million USD | 68.428% |
| Kodiak Sciences Inc. | -277.32 Million USD | 95.105% |
| Sana Biotechnology, Inc. | -326.9 Million USD | 95.847% |
| Annexon, Inc. | -143.72 Million USD | 90.554% |
| Adverum Biotechnologies, Inc. | -123.79 Million USD | 89.033% |
| Assembly Biosciences, Inc. | -64.64 Million USD | 78.999% |
| Elicio Therapeutics, Inc. | -35.74 Million USD | 62.02% |
| Moderna, Inc. | -4.23 Billion USD | 99.68% |
| Vigil Neuroscience, Inc. | -88.86 Million USD | 84.723% |
| Ionis Pharmaceuticals, Inc. | -353.73 Million USD | 96.162% |
| Vor Biopharma Inc. | -126.03 Million USD | 89.228% |
| Eyenovia, Inc. | -25.4 Million USD | 46.565% |
| DiaMedica Therapeutics Inc. | -21.26 Million USD | 36.164% |
| Puma Biotechnology, Inc. | 32.64 Million USD | 141.593% |
| Monte Rosa Therapeutics, Inc. | -143.31 Million USD | 90.527% |
| Wave Life Sciences Ltd. | -67.99 Million USD | 80.034% |
| Conduit Pharmaceuticals Inc. | -5.56 Million USD | -144.085% |
| ACADIA Pharmaceuticals Inc. | -73.37 Million USD | 81.499% |
| Immunocore Holdings plc | -59.64 Million USD | 77.24% |
| Tango Therapeutics, Inc. | -114.17 Million USD | 88.109% |
| Galectin Therapeutics Inc. | -38.07 Million USD | 64.341% |
| Alkermes plc | 414.12 Million USD | 103.278% |
| Arcellx, Inc. | -89.88 Million USD | 84.895% |
| Renovaro Biosciences Inc. | -81.63 Million USD | 83.371% |
| Zentalis Pharmaceuticals, Inc. | -248.98 Million USD | 94.548% |
| Sagimet Biosciences Inc. | -30.74 Million USD | 55.836% |
| Regulus Therapeutics Inc. | -31.1 Million USD | 56.36% |
| Cardio Diagnostics Holdings, Inc. | -7.24 Million USD | -87.45% |
| Moolec Science SA | -6.65 Million USD | -104.034% |
| Biomea Fusion, Inc. | -126.13 Million USD | 89.237% |
| RenovoRx, Inc. | -11.39 Million USD | -19.13% |
| Geron Corporation | -193.94 Million USD | 93.0% |
| Mereo BioPharma Group plc | -28.41 Million USD | 52.224% |
| Verrica Pharmaceuticals Inc. | -65.75 Million USD | 79.355% |
| Royalty Pharma plc | 1.49 Billion USD | 100.91% |
| Atea Pharmaceuticals, Inc. | -164.16 Million USD | 91.73% |
| Greenwich LifeSciences, Inc. | -9.32 Million USD | -45.542% |
| Calithera Biosciences, Inc. | -42.07 Million USD | 67.733% |
| TFF Pharmaceuticals, Inc. | -21.89 Million USD | 37.994% |
| Mersana Therapeutics, Inc. | -170.95 Million USD | 92.059% |
| Humacyte, Inc. | -100.04 Million USD | 86.43% |
| Structure Therapeutics Inc. | -102.77 Million USD | 86.791% |
| NLS Pharmaceutics AG | -11.8 Million USD | -14.982% |
| Genelux Corporation | -24.16 Million USD | 43.82% |
| ESSA Pharma Inc. | -32.13 Million USD | 57.752% |
| aTyr Pharma, Inc. | -54.91 Million USD | 75.28% |
| Notable Labs, Ltd. | -14.65 Million USD | 7.375% |
| Alzamend Neuro, Inc. | -9.93 Million USD | -36.612% |
| Mustang Bio, Inc. | -50.72 Million USD | 73.237% |
| Immunovant, Inc. | -282.7 Million USD | 95.198% |
| Tevogen Bio Holdings Inc. | -8843.03 USD | -153422.039% |
| Vericel Corporation | -6.46 Million USD | -110.025% |
| Halozyme Therapeutics, Inc. | 337.57 Million USD | 104.022% |
| Akari Therapeutics, Plc | -16.8 Million USD | 19.219% |
| Acasti Pharma Inc. | -11.31 Million USD | -20.014% |
| MiNK Therapeutics, Inc. | -22.92 Million USD | 40.771% |
| Vaxcyte, Inc. | -468.04 Million USD | 97.099% |
| Orgenesis Inc. | -53.63 Million USD | 74.689% |
| Spruce Biosciences, Inc. | -51.99 Million USD | 73.889% |
| NeuroBo Pharmaceuticals, Inc. | -15.88 Million USD | 14.541% |
| GH Research PLC | -41.22 Million USD | 67.066% |
| Tempest Therapeutics, Inc. | -29.15 Million USD | 53.438% |
| PepGen Inc. | -84.76 Million USD | 83.984% |
| Moleculin Biotech, Inc. | -29.63 Million USD | 54.183% |
| Relmada Therapeutics, Inc. | -103.7 Million USD | 86.909% |
| BriaCell Therapeutics Corp. | -32.8 Million USD | 58.62% |
| Lixte Biotechnology Holdings, Inc. | -5.09 Million USD | -166.707% |
| Silo Pharma, Inc. | -3.85 Million USD | -252.112% |
| Telomir Pharmaceuticals, Inc. Common Stock | -3.94 Million USD | -244.39% |
| Belite Bio, Inc | -31.66 Million USD | 57.13% |
| Pharming Group N.V. | -4.87 Million USD | -178.223% |
| XOMA Corporation | -41.84 Million USD | 67.559% |
| Reneo Pharmaceuticals, Inc. | -83.05 Million USD | 83.654% |
| Reviva Pharmaceuticals Holdings, Inc. | -24.3 Million USD | 44.147% |
| Bionomics Limited | -17.89 Billion USD | 99.924% |
| Xencor, Inc. | -138.63 Million USD | 90.208% |
| Replimune Group, Inc. | -234.77 Million USD | 94.217% |
| Pyxis Oncology, Inc. | -82.19 Million USD | 83.483% |
| Cassava Sciences, Inc. | -105.95 Million USD | 87.187% |
| Vanda Pharmaceuticals Inc. | -13.95 Million USD | 2.695% |
| Estrella Immunopharma, Inc. | -7.31 Million USD | -85.716% |
| Turnstone Biologics Corp. | -59.03 Million USD | 77.002% |
| Windtree Therapeutics, Inc. | -17.53 Million USD | 22.595% |
| GeoVax Labs, Inc. | -26.74 Million USD | 49.235% |
| MEI Pharma, Inc. | 14.54 Million USD | 193.357% |
| Olema Pharmaceuticals, Inc. | -104.96 Million USD | 87.066% |
| Cardio Diagnostics Holdings, Inc. | -7.24 Million USD | -87.45% |
| Bio-Path Holdings, Inc. | -15.84 Million USD | 14.309% |
| Enlivex Therapeutics Ltd. | -29.39 Million USD | 53.815% |
| CollPlant Biotechnologies Ltd. | -7.51 Million USD | -80.724% |
| scPharmaceuticals Inc. | -55.39 Million USD | 75.493% |
| HilleVax, Inc. | -133.34 Million USD | 89.819% |
| Vera Therapeutics, Inc. | -102.01 Million USD | 86.692% |
| Tharimmune, Inc. | -9.45 Million USD | -43.582% |
| Genprex, Inc. | -31.07 Million USD | 56.313% |
| SeaStar Medical Holding Corporation | -14.21 Million USD | 4.462% |
| Immunic, Inc. | -99.22 Million USD | 86.318% |
| Atossa Therapeutics, Inc. | -31.37 Million USD | 56.733% |
| Aptorum Group Limited | -10.52 Million USD | -29.009% |
| Soleno Therapeutics, Inc. | -41.38 Million USD | 67.195% |
| SeaStar Medical Holding Corporation | -14.21 Million USD | 4.462% |
| OKYO Pharma Limited | -15.74 Thousand USD | -86098.303% |
| Carmell Therapeutics Corporation | -5.21 Million USD | -160.212% |
| Achieve Life Sciences, Inc. | -27.25 Million USD | 50.18% |
| Ocean Biomedical, Inc. | -2.48 Million USD | -447.058% |
| Amicus Therapeutics, Inc. | -73.49 Million USD | 81.528% |
| Salarius Pharmaceuticals, Inc. | -12.89 Thousand USD | -105181.607% |
| bluebird bio, Inc. | -244.26 Million USD | 94.442% |
| DBV Technologies S.A. | -76.43 Million USD | 82.238% |
| Compugen Ltd. | -12.99 Million USD | -4.495% |
| Protagenic Therapeutics, Inc. | -4.52 Million USD | -199.891% |
| Peak Bio, Inc. | -1356.23 USD | -1000910.153% |
| Vincerx Pharma, Inc. | -42.6 Million USD | 68.138% |
| Fresh Tracks Therapeutics, Inc. | -6.36 Million USD | -113.459% |
| Sensei Biotherapeutics, Inc. | -37.06 Million USD | 63.371% |
| Orchestra BioMed Holdings, Inc. | -51.5 Million USD | 73.642% |
| Zevra Therapeutics, Inc. | -49.6 Million USD | 72.631% |
| Acrivon Therapeutics, Inc. Common Stock | -67.23 Million USD | 79.809% |
| Benitec Biopharma Inc. | -22.49 Million USD | 39.635% |
| Spyre Therapeutics, Inc. | -242.3 Million USD | 94.397% |
| Adicet Bio, Inc. | -152.03 Million USD | 91.071% |
| Prime Medicine, Inc. | -191.29 Million USD | 92.903% |
| Aditxt, Inc. | -26.06 Million USD | 47.91% |
| Madrigal Pharmaceuticals, Inc. | -380.49 Million USD | 96.432% |
| Estrella Immunopharma, Inc. | -7.31 Million USD | -85.716% |
| Quantum-Si incorporated | -111.17 Million USD | 87.788% |
| GlycoMimetics, Inc. | -39.27 Million USD | 65.434% |
| PolyPid Ltd. | -22.86 Million USD | 40.631% |
| Aileron Therapeutics, Inc. | -16.27 Million USD | 16.589% |
| Invivyd, Inc. | -207.78 Million USD | 93.466% |
| Quoin Pharmaceuticals, Ltd. | -9.37 Million USD | -44.757% |
| Rigel Pharmaceuticals, Inc. | -20.49 Million USD | 33.747% |
| CorMedix Inc. | -48.95 Million USD | 72.27% |
| Instil Bio, Inc. | -159.16 Million USD | 91.471% |
| Recursion Pharmaceuticals, Inc. | -350.06 Million USD | 96.122% |
| Contineum Therapeutics, Inc. Class A Common Stock | 16.07 Million USD | 184.444% |
| Finch Therapeutics Group, Inc. | -34 Million USD | 60.073% |
| Spero Therapeutics, Inc. | 21.48 Million USD | 163.2% |
| Alpha Tau Medical Ltd. | 35.68 Million USD | 138.049% |
| AbCellera Biologics Inc. | -237.2 Million USD | 94.277% |
| Ocular Therapeutix, Inc. | -82.38 Million USD | 83.521% |
| Surrozen, Inc. | -45.78 Million USD | 70.345% |
| Janux Therapeutics, Inc. | -72.97 Million USD | 81.397% |
| Verona Pharma plc | -67.83 Million USD | 79.986% |
| Terns Pharmaceuticals, Inc. | -102.55 Million USD | 86.763% |
| Vir Biotechnology, Inc. | -684.3 Million USD | 98.016% |
| Evaxion Biotech A/S | -22.19 Million USD | 38.839% |
| Verve Therapeutics, Inc. | -223.12 Million USD | 93.915% |
| Shattuck Labs, Inc. | -91.95 Million USD | 85.237% |
| AlloVir, Inc. | -181.33 Million USD | 92.513% |
| BioVie Inc. | -32.17 Million USD | 57.812% |
| Codexis, Inc. | -68.06 Million USD | 80.056% |
| SELLAS Life Sciences Group, Inc. | -37.86 Million USD | 64.15% |
| Lexaria Bioscience Corp. | -6.53 Million USD | -107.774% |
| Agenus Inc. | -159.54 Million USD | 91.491% |
| Virax Biolabs Group Limited | -6.49 Million USD | -108.975% |
| Lantern Pharma Inc. | -17.87 Million USD | 24.061% |
| Viridian Therapeutics, Inc. | -254.45 Million USD | 94.665% |
| eFFECTOR Therapeutics, Inc. | -33.84 Million USD | 59.887% |
| Immix Biopharma, Inc. | -16.14 Million USD | 15.892% |
| Celcuity Inc. | -66.23 Million USD | 79.502% |
| Cardiff Oncology, Inc. | -45.41 Million USD | 70.105% |
| Acumen Pharmaceuticals, Inc. | -61.13 Million USD | 77.794% |
| IN8bio, Inc. | -30.33 Million USD | 55.249% |
| Avenue Therapeutics, Inc. | -14.54 Million USD | 6.63% |
| Trevi Therapeutics, Inc. | -33.92 Million USD | 59.98% |
| Lexicon Pharmaceuticals, Inc. | -171.75 Million USD | 92.095% |
| Liquidia Corporation | -73.38 Million USD | 81.5% |
| Quantum-Si incorporated | -111.17 Million USD | 87.788% |
| Pasithea Therapeutics Corp. | -15.97 Million USD | 15.04% |
| Xenon Pharmaceuticals Inc. | -214.05 Million USD | 93.658% |
| Sol-Gel Technologies Ltd. | -29.3 Million USD | 53.673% |
| United Therapeutics Corporation | 1.18 Billion USD | 101.146% |
| Solid Biosciences Inc. | -104.31 Million USD | 86.986% |
| Immuneering Corporation | -58.41 Million USD | 76.759% |
| Alpha Tau Medical Ltd. | 35.68 Million USD | 138.049% |
| uniQure N.V. | -282.87 Million USD | 95.201% |
| Xilio Therapeutics, Inc. | -79.13 Million USD | 82.844% |
| Enveric Biosciences, Inc. | -16.44 Million USD | 17.463% |
| Poseida Therapeutics, Inc. | -129.5 Million USD | 89.517% |
| Longboard Pharmaceuticals, Inc. | -56.75 Million USD | 76.081% |
| PMV Pharmaceuticals, Inc. | -80.13 Million USD | 83.058% |
| Elevai Labs, Inc. Common Stock | -3.66 Million USD | -270.012% |
| Cue Biopharma, Inc. | -52.14 Million USD | 73.967% |
| Nuvectis Pharma, Inc. | -22.89 Million USD | 40.708% |
| ARS Pharmaceuticals, Inc. | -67.52 Million USD | 79.893% |
| Zura Bio Limited | -62.63 Million USD | 78.326% |
| Forte Biosciences, Inc. | -32.48 Million USD | 58.21% |
| Elevation Oncology, Inc. | -45.44 Million USD | 70.127% |
| Conduit Pharmaceuticals Inc. | -5.56 Million USD | -144.085% |
| Immunome, Inc. | -109.53 Million USD | 87.605% |
| Compass Therapeutics, Inc. | -50.36 Million USD | 73.044% |
| enGene Holdings Inc. Warrants | -26.06 Million USD | 47.905% |
| Inovio Pharmaceuticals, Inc. | -135.22 Million USD | 89.961% |
| LENZ Therapeutics, Inc. | -73.11 Million USD | 81.431% |
| Altimmune, Inc. | -95.92 Million USD | 85.848% |
| Milestone Pharmaceuticals Inc. | -61.09 Million USD | 77.78% |
| Rallybio Corporation | -78.93 Million USD | 82.8% |
| Plus Therapeutics, Inc. | -13.32 Million USD | -1.914% |
| Dianthus Therapeutics, Inc. | -48.17 Million USD | 71.819% |
| Moolec Science SA | -6.65 Million USD | -104.034% |
| Anebulo Pharmaceuticals, Inc. | -8.3 Million USD | -63.394% |
| XTL Biopharmaceuticals Ltd. | -765 Thousand USD | -1674.641% |
| Tourmaline Bio, Inc. | -45.4 Million USD | 70.103% |
| NeurAxis, Inc. | -6.66 Million USD | -103.706% |
| Maravai LifeSciences Holdings, Inc. | -31.64 Million USD | 57.103% |
| Lumos Pharma, Inc. | -36.61 Million USD | 62.921% |
| enGene Holdings Inc. Common Stock | -26.06 Million USD | 47.905% |
| 180 Life Sciences Corp. | -13.47 Million USD | -0.731% |
| NKGen Biotech, Inc. Warrants | -29.74 Million USD | 54.36% |
| Opiant Pharmaceuticals, Inc. | 5.15 Million USD | 363.289% |
| CERo Therapeutics Holdings, Inc. | -2.93 Million USD | -362.873% |
| Nutriband Inc. | -4.87 Million USD | -178.658% |
| CG Oncology, Inc. Common stock | -55.44 Million USD | 75.516% |
| argenx SE | -425.04 Million USD | 96.806% |
| Neurogene Inc. | -55.58 Million USD | 75.575% |
| Mirum Pharmaceuticals, Inc. | -109.15 Million USD | 87.563% |
| Kintara Therapeutics, Inc. | -8.5 Million USD | -59.699% |
| CervoMed Inc. | -7.81 Million USD | -73.764% |
| CARGO Therapeutics, Inc. Common Stock | -96.71 Million USD | 85.962% |
| Sesen Bio, Inc. | -25.9 Million USD | 47.601% |
| AnaptysBio, Inc. | -164.41 Million USD | 91.743% |
| Design Therapeutics, Inc. | -78.19 Million USD | 82.637% |
| Leap Therapeutics, Inc. | -87.04 Million USD | 84.403% |
| Seelos Therapeutics, Inc. | -40.49 Million USD | 66.478% |
| Achilles Therapeutics plc | -75.25 Million USD | 81.96% |
| NeuroSense Therapeutics Ltd. | -12.04 Million USD | -12.673% |
| ORIC Pharmaceuticals, Inc. | -110.78 Million USD | 87.745% |
| Fractyl Health, Inc. Common Stock | -50.83 Million USD | 73.295% |
| Rani Therapeutics Holdings, Inc. | -66.09 Million USD | 79.461% |
| MoonLake Immunotherapeutics | -54.12 Million USD | 74.916% |
| Palisade Bio, Inc. | -13.07 Million USD | -3.871% |
| Beam Therapeutics Inc. | -176.48 Million USD | 92.308% |
| AEON Biopharma, Inc. | -48.42 Million USD | 71.967% |
| Enliven Therapeutics, Inc. | -83.52 Million USD | 83.747% |
| Kiora Pharmaceuticals, Inc. | -12.58 Million USD | -7.858% |
| Iovance Biotherapeutics, Inc. | -460.55 Million USD | 97.052% |
| Taysha Gene Therapies, Inc. | -72.43 Million USD | 81.259% |
| Athira Pharma, Inc. | -125.46 Million USD | 89.18% |
| Vaccinex, Inc. | -22.88 Million USD | 40.677% |
| HCW Biologics Inc. | -25.71 Million USD | 47.21% |
| XOMA Corporation | -41.84 Million USD | 67.559% |
| Nektar Therapeutics | -137.42 Million USD | 90.121% |
| Arvinas, Inc. | -401.5 Million USD | 96.619% |
| Tevogen Bio Holdings Inc. | -8843.03 USD | -153422.039% |
| Merus N.V. | -156.54 Million USD | 91.328% |
| Omega Therapeutics, Inc. | -100.26 Million USD | 86.459% |
| Quince Therapeutics, Inc. | -34.62 Million USD | 60.786% |
| Rezolute, Inc. | -70.42 Million USD | 80.722% |
| Clene Inc. | -40.54 Million USD | 66.512% |
| Indaptus Therapeutics, Inc. | -16.37 Million USD | 17.111% |
| BeyondSpring Inc. | -23.11 Million USD | 41.265% |
| Synlogic, Inc. | -55.16 Million USD | 75.388% |
| Allarity Therapeutics, Inc. | -17.92 Million USD | 24.279% |
| Phio Pharmaceuticals Corp. | -10.82 Million USD | -25.425% |
| Peak Bio, Inc. | -1356.23 USD | -1000910.153% |
| Werewolf Therapeutics, Inc. | -40.5 Million USD | 66.481% |
| Krystal Biotech, Inc. | -109.72 Million USD | 87.627% |
| Karyopharm Therapeutics Inc. | -129.53 Million USD | 89.52% |
| SpringWorks Therapeutics, Inc. | -343.01 Million USD | 96.042% |
| Lipella Pharmaceuticals Inc. | -4.74 Million USD | -186.054% |
| MannKind Corporation | 8.67 Million USD | 256.442% |
| Ikena Oncology, Inc. | -75.41 Million USD | 81.999% |
| Cyclerion Therapeutics, Inc. | -9.64 Million USD | -40.728% |
| Gyre Therapeutics, Inc. | -67.23 Million USD | 79.807% |
| Gossamer Bio, Inc. | -183.75 Million USD | 92.612% |
| CohBar, Inc. | -12.38 Million USD | -9.587% |
| Cognition Therapeutics, Inc. | -50.72 Million USD | 73.236% |
| NRx Pharmaceuticals, Inc. | -27.58 Million USD | 50.788% |
| Legend Biotech Corporation | -439.48 Million USD | 96.911% |
| Mural Oncology plc | -194.63 Million USD | 93.025% |
| Biora Therapeutics, Inc. | -67.14 Million USD | 79.78% |
| PaxMedica, Inc. Common Stock | -16.14 Million USD | 15.913% |
| Disc Medicine, Inc. | -91.12 Million USD | 85.102% |
| Champions Oncology, Inc. | -7.35 Million USD | -84.557% |
| REGENXBIO Inc. | -268.12 Million USD | 94.937% |
| Ensysce Biosciences, Inc. | -10.71 Million USD | -26.663% |
| Anavex Life Sciences Corp. | -55.75 Million USD | 75.651% |
| Cellectar Biosciences, Inc. | -38.96 Million USD | 65.155% |
| Edgewise Therapeutics, Inc. | -114.35 Million USD | 88.128% |
| Vaxart, Inc. | -83.34 Million USD | 83.711% |
| PharmaCyte Biotech, Inc. | -8.52 Million USD | -59.343% |
| Aldeyra Therapeutics, Inc. | -42.79 Million USD | 68.276% |
| Cellectis S.A. | -106.62 Million USD | 87.268% |
| Longeveron Inc. | -21.02 Million USD | 35.442% |
| Repare Therapeutics Inc. | -116.22 Million USD | 88.319% |
| Sarepta Therapeutics, Inc. | -267.82 Million USD | 94.931% |
| Inozyme Pharma, Inc. | -75.64 Million USD | 82.053% |
| Revolution Medicines, Inc. | -487.18 Million USD | 97.213% |
| Nymox Pharmaceutical Corporation | -6.65 Million USD | -104.089% |
| Third Harmonic Bio, Inc. | -43.95 Million USD | 69.113% |
| ArriVent BioPharma, Inc. Common Stock | -74.59 Million USD | 81.799% |
| AN2 Therapeutics, Inc. | -69.63 Million USD | 80.504% |
| Anixa Biosciences, Inc. | -11.01 Million USD | -23.295% |
| Vertex Pharmaceuticals Incorporated | 4.3 Billion USD | 100.315% |
| Denali Therapeutics Inc. | -196.69 Million USD | 93.098% |
| Revelation Biosciences, Inc. | -8.65 Million USD | -56.827% |
| Veru Inc. | -93.78 Million USD | 85.524% |
| Corvus Pharmaceuticals, Inc. | -23.32 Million USD | 41.806% |
| Cingulate Inc. | -22.75 Million USD | 40.349% |
| Passage Bio, Inc. | -108.38 Million USD | 87.475% |
| Context Therapeutics Inc. | -25.07 Million USD | 45.853% |
| Exicure, Inc. | -14.99 Million USD | 9.469% |
| Day One Biopharmaceuticals, Inc. | -206.06 Million USD | 93.412% |
| Oramed Pharmaceuticals Inc. | -40.59 Million USD | 66.56% |
| Revolution Medicines, Inc. Warrant | -487.18 Million USD | 97.213% |
| Scinai Immunotherapeutics Ltd. | -9.71 Million USD | -39.715% |
| Rhythm Pharmaceuticals, Inc. | -184.35 Million USD | 92.636% |
| Nuvalent, Inc. | -149.49 Million USD | 90.919% |
| ABVC BioPharma, Inc. | -8.21 Million USD | -65.228% |
| Carisma Therapeutics, Inc. | -88.73 Million USD | 84.7% |
| Unicycive Therapeutics, Inc. | -20.77 Million USD | 34.649% |
| OmniAb, Inc. | -69.41 Million USD | 80.443% |
| Anew Medical, Inc. | -1.3 Million USD | -943.633% |
| Fennec Pharmaceuticals Inc. | -12.77 Million USD | -6.303% |
| Lipocine Inc. | -17.93 Million USD | 24.287% |
| Lexeo Therapeutics, Inc. Common Stock | -68.51 Million USD | 80.185% |
| Nautilus Biotechnology, Inc. | -76.15 Million USD | 82.172% |
| SAB Biotherapeutics, Inc. | -38.07 Million USD | 64.344% |
| G1 Therapeutics, Inc. | -39.52 Million USD | 65.654% |
| Bellerophon Therapeutics, Inc. | -22.38 Million USD | 39.35% |
| Sage Therapeutics, Inc. | -579.84 Million USD | 97.659% |
| Ocugen, Inc. | -65.53 Million USD | 79.283% |
| Mind Medicine (MindMed) Inc. | -93.86 Million USD | 85.537% |
| Q32 Bio Inc. | -92.1 Million USD | 85.26% |
| Brainstorm Cell Therapeutics Inc. | -21.43 Million USD | 36.676% |
| Alumis Inc. Common Stock | -158.17 Million USD | 91.417% |
| Equillium, Inc. | -14.52 Million USD | 6.514% |
| Kyverna Therapeutics, Inc. | -62.4 Million USD | 78.246% |
| Coya Therapeutics, Inc. | -7.9 Million USD | -71.775% |
| CNS Pharmaceuticals, Inc. | -18.86 Million USD | 28.036% |
| Galera Therapeutics, Inc. | -46.95 Million USD | 71.085% |
| Evelo Biosciences, Inc. | -108.46 Million USD | 87.484% |
| Comera Life Sciences Holdings, Inc. | -11.97 Million USD | -13.417% |
| Dominari Holdings Inc. | -21.79 Million USD | 37.713% |
| Edesa Biotech, Inc. | -9.22 Million USD | -47.201% |
| vTv Therapeutics Inc. | -25.5 Million USD | 46.765% |
| Bio-Techne Corporation | 206.68 Million USD | 106.568% |
| Agios Pharmaceuticals, Inc. | -391.48 Million USD | 96.532% |
| Harmony Biosciences Holdings, Inc. | 192.03 Million USD | 107.07% |
| Prelude Therapeutics Incorporated | -132.27 Million USD | 89.737% |
| Candel Therapeutics, Inc. | -38.39 Million USD | 64.638% |
| iTeos Therapeutics, Inc. | -151.1 Million USD | 91.015% |
| Nkarta, Inc. | -131.65 Million USD | 89.688% |
| BioCardia, Inc. | -11.64 Million USD | -16.592% |
| Iterum Therapeutics plc | -47.46 Million USD | 71.4% |